China Traditional Chinese Medicine Holdings Co. Limited (“China TCM”) is the core platform established by Sinopharm Group for the traditional Chinese medicine segment. The Company (stock code: 00570.HK) is listed on the Main Board of the Hong Kong Stock Exchange, and headquartered in Foshan, Guangdong.
The Company has a complete industrial chain and integrates research, manufacturing and sales as a whole. It has more than 1200 patent medicine regulations (of which more than 280 regulations are included in National Essential Medicine List 2018), over 700 varieties of TCM formula granules and over 400 varieties of classic compound granules (for export only). The products have covered several major fields including Chinese patent medicine, herbal pieces, formula granules and chemical medicine.
|Number of Shares||5,035,801,852|
|Market Cap (mln)||23,316|
|Financial Highlights, RMB'000||2018||2019||2020|
|Profit from operations||2,156,025||2,460,716||2,490,631|
|Profit before taxation||1,856,697||2,154,618||2,230,091|
|Profit attributable to the shareholders of the Company||1,439,018||1,588,114||1,663,255|
|Gross profit margin (%)||55.01||59.88||61.64|
|Operating profit margin (%)||19.15||17.18||16.82|
|Net profit margin (%)||13.92||12.38||12.57|
|Earnings per share|
|Basic & Diluted (cents)||29.84||31.54||33.03|
|Total equity attributable to equity shareholders of the Company||15,551,433||16,623,415||18,064,086|
|Bank balances and cash||6,349,714||5,613,633||3,440,240|
|Debt asset ratio (%)||42.18||41.33||36.85|